Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers
FDA approves Enhertu for several types of HER2 positive cancers.
FDA approved Enhertu for several indications including HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow breast cancer, HER…
The FDA has approved Enhertu for multiple cancers, including breast, lung, stomach, and other solid tumors that have a specific protein call…
Phase II trial protocol examines HER2-PET imaging to predict trastuzumab deruxtecan response in HER2-low metastatic breast cancer
A Full-Body Scan May Soon Decide Who Benefits From This Breast Cancer Drug
A multicenter, prospective, open-label phase II trial protocol will enroll 70 patients with HER2-low metastatic breast cancer.
A whole-body imaging scan may one day replace a single biopsy for matching patients to targeted breast cancer therapy.
Research across Cancer
Related studies from across the Cancer family.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
Statins lower recurrence and death risk in hormone receptor-positive breast cancer
This systematic review and meta-analysis evaluated statin use versus non-use in 267,913 patients with hormone receptor-positive breast cance…
A massive analysis of over 267,000 patients shows statins reduce recurrence and death risk in hormone receptor-positive breast cancer.
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Lymphovenous anastomosis improves quality of life in breast cancer-related lymphedema
Lymphedema surgery improves quality of life in breast cancer survivors
This meta-analysis of observational studies found that therapeutic lymphovenous anastomosis (LVA) significantly improves quality of life in …
A new analysis finds that lymphovenous anastomosis significantly boosts quality of life for breast cancer survivors with lymphedema, especia…
Weight reduction ranked highest for limb volume, while VR-based training ranked highest for pain in breast cancer-related lymphedema
Weight loss and virtual reality rank highest for breast cancer swelling and pain relief
This network meta-analysis of 754 patients evaluated non-pharmacological therapies for breast cancer-related lymphedema. Weight reduction ra…
Weight loss and virtual reality training ranked best for reducing arm swelling and pain in breast cancer patients, though other therapies al…
Healthcare professionals need updated guidance on managing breast cancer-related lymphedema effectively today
Review updates care for breast cancer-related lymphedema
This narrative review aims to apprise healthcare professionals with the latest understanding of optimal care and counseling patients regardi…
A new review summarizes the latest understanding of breast cancer-related lymphedema to help healthcare professionals counsel patients.
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Protocol for randomized controlled trial of TEAS pretreatment for breast cancer-related lymphedema
New electrical therapy may stop breast cancer swelling before surgery starts
This document outlines a randomized controlled trial protocol evaluating transcutaneous electrical acupoint stimulation pretreatment in brea…
A new electrical therapy might stop arm swelling before breast cancer surgery begins
Taxane-Based and Long-Course Chemotherapy Linked to Higher Breast Cancer-Related Lymphedema Risk
New Data Links Chemo Drugs to Arm Swelling in Breast Cancer
In a retrospective cohort of 201 breast cancer patients at Guangzhou Red Cross Hospital, taxane-based regimens, long-course chemotherapy, an…
Breast cancer patients on certain chemotherapy drugs face a higher risk of developing arm swelling after treatment ends.
CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC
Two drugs linked to longer survival than palbociclib in breast cancer
This retrospective single-center analysis of 341 patients with HR+/HER2− MBC found that palbociclib, abemaciclib, and dalpiciclib combined w…
In a real-world analysis, two CDK4/6 inhibitors showed longer survival times than palbociclib for metastatic breast cancer patients.
Review of 35 cases highlights diagnostic challenges in gastric metastasis from invasive lobular breast cancer
Breast Cancer Spreads to Stomach: Why Testing Must Change
This case report and literature review synthesizes data from 35 recent cases (2019–2024) of gastric metastasis from breast cancer.
Doctors must re-test stomach issues in breast cancer patients because the cells often change their identity.
Retrospective analysis identifies risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients
Many Breast Cancer Patients Can Avoid Heart Damage — If Doctors Know the Warning Signs
This retrospective analysis of 298 HER2-positive breast cancer patients assessed trastuzumab-induced cardiotoxicity.
This could help doctors protect patients’ hearts before cancer therapy even begins.